4.7 Article

Protracted dormancy of pre-leukemic stem cells

Journal

LEUKEMIA
Volume 29, Issue 11, Pages 2202-2207

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2015.132

Keywords

-

Funding

  1. Leukaemia and Lymphoma Research
  2. European Hematology Association-EHA Partner Fellowship [2011/01]
  3. Instituto Nacional de Cancer-INCA
  4. Lady Tata Memorial Trust-LTMT International Award for Research in Leukaemia
  5. Kay Kendall Leukaemia Fund (FWvD)
  6. Wellcome Trust Strategic Award [105104/Z/14/Z]
  7. Wellcome Trust [105104/Z/14/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Cancer stem cells can escape therapeutic killing by adopting a quiescent or dormant state. The reversibility of this condition provides the potential for later recurrence or relapse, potentially many years later. We describe the genomics of a rare case of childhood BCR-ABL1-positive, B-cell precursor acute lymphoblastic leukemia that relapsed, with an acute myeloblastic leukemia immunophenotype, 22 years after the initial diagnosis, sustained remission and presumed cure. The primary and relapsed leukemias shared the identical BCR-ABL1 fusion genomic sequence and two identical immunoglobulin gene rearrangements, indicating that the relapse was a derivative of the founding clone. All other mutational changes (single-nucleotide variant and copy number alterations) were distinct in diagnostic or relapse samples. These data provide unambiguous evidence that leukemia-propagating cells, most probably pre-leukemic stem cells, can remain covert and silent but potentially reactivatable for more than two decades.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available